Ex parte JONES - Page 3




                     Appeal No. 1996-0848                                                                                                                                                
                     Application 07/624,053                                                                                                                                              



                                           v) retention of biological activity in the presence of anti-serum to                                                                          
                                interferon gamma, interferon alpha, or a combination of anti-sera to                                                                                     
                                           interferon alpha and gamma; and                                                                                                               
                                (c) culturing the clone to produce the continuous cell line.                                                                                             
                                42.        A method of generating a continuous cell line which produces a factor                                                                         
                     capable of inducing human monocytes to a cytotoxic state, the method comprising the                                                                                 
                     steps of:                                                                                                                                                           
                                (a)        immortalizing human T-cells to produce continuous cell clones;                                                                                
                                (b)     identifying a clone which produces a factor having the following                                                                                 
                                characteristics:                                                                                                                                         
                                           i)         capability of inducing human monocytes to a cytotoxic state;                                                                       
                                           ii)        retention of biological activity following treatment at pH 2 for one                                                               
                                                      hour;                                                                                                                              
                                                                                                                                             B                                           
                                           iii.       retention of biological activity following treatment at 60  C for one                                                              
                                                      hour;                                                                                                                              
                                           iv.        ability to bind to Matrex Gel Red A under low-salt conditions and                                                                  
                                                      elute from Matrex Gel Red A under high-salt conditions; and                                                                        
                                           v.         retention of biological activity in the presence of anti-serum to                                                                  
                                           interferon gamma, interferon gamma, interferon alpha, or a                                                                                    
                                           combination of anti-sera to interferon alpha and gamma; and                                                                                   
                                (c)        culturing the clone to produce the continuous cell line.                                                                                      








                                                                                           3                                                                                             





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next 

Last modified: November 3, 2007